Integrated continuous manufacturing of therapeutic protein drug substances
Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.
1. An integrated and continuous process for manufacturing a therapeutic protein drug substance, the process comprising:
(i) culturing recombinant therapeutic protein-secreting mammalian cells in a perfusion bioreactor comprising a liquid culture medium under conditions that allow the cells to secrete the recombinant therapeutic protein into the medium, and wherein substantially cell-free volumes of the medium are continuously or periodically removed from the perfusion bioreactor and directly fed from the perfusion bioreactor into a first periodic counter current chromatography system (PCCS1) without storage in a reservoir that is a tank or a sealed bag;
(ii) capturing the recombinant therapeutic protein from the medium using the PCCS1, wherein an eluate of the PCCS1 comprising the recombinant therapeutic protein is continuously fed into a second periodic counter current chromatography system (PCCS2); and
(iii) purifying and polishing the recombinant therapeutic protein using the PCCS2, wherein the purifying is performed using a resin in the PCCS2 that is different in chemical structure compared to the resin in the PCCS2 used to perform the polishing, and an eluate from the PCCS2 is the therapeutic protein drug substance; and
wherein the process is integrated and runs continuously from the culturing step to the purifying and polishing step.
2. The process of claim 1 , wherein the PCCS1 performs at least two different unit operations.
3. The process of claim 2 , wherein the use of the PCCS1 or the PCCS2, or both, includes column switching.
4. The process of claim 2 , wherein the PCCS1 performs the unit operations of capturing the recombinant therapeutic protein and inactivating viruses.
5. The process of claim 1 , wherein the PCCS1 or the PCCS2, or both, utilizes at least two chromatography columns.
6. The process of claim 1 , wherein the PCCS1 comprises four chromatography columns, wherein three of the four columns in the PCCS1 perform the unit operation of capturing the recombinant therapeutic protein from the medium.
7. The process of claim 6 , wherein the capturing is performed using affinity chromatography, cation exchange chromatography, anion exchange chromatography, or molecular sieve chromatography.
8. The process of claim 7 , wherein the affinity chromatography is performed with a capture mechanism selected from the group consisting of: protein A-binding capture mechanism, substrate-binding capture mechanism, antibody- or antibody fragment-binding capture mechanism, aptamer-binding capture mechanism, and cofactor-binding capture mechanism.
9. The process of claim 8 , wherein the affinity chromatography is performed with a protein A-binding capture mechanism, and the recombinant therapeutic protein is an antibody or an antibody fragment.
10. The process of claim 6 , wherein an eluate comprising the recombinant therapeutic protein from the three of the four columns in the PCCS1 is fed into the fourth column of the PCCS1.
11. The process of claim 10 , wherein the fourth column of the PCCS1 performs the unit operation of inactivating viruses by incubating holding the eluate from the three of the four columns in the PCCS1 at a pH of about 3.0 to 5.0.
12. The process of claim 11 , further comprising adjusting the pH of an eluate comprising the recombinant therapeutic protein from the fourth column of the PCCS1 using an in-line buffer adjustment reservoir before the eluate from the fourth column of the PCCS1 is fed into the PCCS2.
13. The process of claim 12 , where the PCCS2 comprises three chromatography columns and a chromatographic membrane, wherein the three chromatography columns in the PCCS2 perform the unit operation of purifying the recombinant therapeutic protein from the eluate from the fourth column of the PCCS1 through cation or anion exchange chromatography, and an eluate comprising the recombinant therapeutic protein from the three chromatography columns in the PCCS2 is fed into the chromatographic membrane in the PCCS2.
14. The process of claim 13 , wherein the chromatographic membrane in the PCCS2 performs the unit function of polishing the recombinant therapeutic protein present in the eluate from the three chromatography columns in the PCCS2 through cation or anion exchange chromatography.
15. The process of claim 14 , wherein a flow through and wash of the chromatographic membrane is the therapeutic protein drug substance.
16. The process of claim 1 , further comprising formulating the therapeutic protein drug substance into a pharmaceutical composition.
17. The process of claim 1 , wherein the recombinant therapeutic protein is an antibody or antibody fragment, an enzyme, an engineered protein, or an immunogenic protein or protein fragment.
18. An integrated and continuous process for manufacturing a therapeutic protein drug substance comprising:
(i) culturing recombinant therapeutic protein-secreting mammalian cells in a perfusion bioreactor comprising a liquid culture medium under conditions that allow the cells to secrete the recombinant therapeutic protein into the medium, and wherein substantially cell-free volumes of the medium are continuously or periodically removed from the perfusion bioreactor and fed from the perfusion bioreactor into a first periodic counter current chromatography system (PCCS1);
(ii) capturing the recombinant therapeutic protein from the medium using the PCCS1, wherein an eluate of the PCCS1 comprising the recombinant therapeutic protein is continuously fed into a second periodic counter chromatography system (PCCS2); and
(iii) purifying and polishing the therapeutic recombinant protein using the PCCS2, wherein the purifying is performed using a resin in the PCCS2 that is different in chemical structure compared to the resin in the PCCS2 used to perform the polishing, and an eluate from the PCCS2 is the therapeutic protein drug substance;
wherein the process is integrated and runs continuously from the culturing step to the purifying and polishing step.
19. The process of claim 18 , wherein the PCCS1 performs at least two different unit operations.
20. The process of claim 19 , wherein the use of the PCCS1 or the PCCS2, or both, includes column switching.
21. The process of claim 19 , wherein the PCCS1 performs the unit operations of capturing the recombinant therapeutic protein and inactivating viruses.
22. The process of claim 18 , wherein the PCCS1 or the PCCS2, or both, utilizes at least two chromatography columns.
23. The process of claim 18 , wherein the PCCS1 comprises four chromatography columns, wherein three of the four columns in the PCCS1 perform the unit operation of capturing the recombinant therapeutic protein from the medium.
24. The process of claim 23 , wherein an eluate comprising the recombinant therapeutic protein from the three of the four columns in the PCCS1 is fed into the fourth column of PCCS1.
25. The process of claim 24 , wherein the fourth column of the PCCS1 performs the unit operation of inactivating viruses by incubating the eluate from the three of the four columns of the PCCS1 at a pH of about 3.0 to 5.0.
26. The process of claim 25 , where the PCCS2 comprises three chromatography columns and a chromatographic membrane, wherein the three chromatography columns in the PCCS2 perform the unit operation of purifying the recombinant therapeutic protein from an eluate from the fourth column of the PCCS1 through cation or anion exchange chromatography, wherein an eluate comprising the recombinant therapeutic protein from the three chromatography columns in the PCCS2 is fed into the chromatographic membrane in the PCCS2.
27. The process of claim 26 , wherein the chromatographic membrane in the PCCS2 performs the unit function of polishing the recombinant therapeutic protein present in the eluate from the three chromatography columns in the PCCS2 through cation or anion exchange chromatography.
28. The process of claim 18 , further comprising formulating the therapeutic protein drug substance into a pharmaceutical composition.
29. The process of claim 18 , wherein the recombinant therapeutic protein is an antibody or antibody fragment, an enzyme, an engineered protein, or an immunogenic protein or protein fragment.